It is a scenario scarily familiar to many surgical oncologists. A patient with breast cancer undergoes neoadjuvant chemotherapy to shrink the tumor before a lumpectomy. The surgery goes well, and the patient feels great for the next 10 years. But then one day, the disease returns, spreading to the lungs, bones or liver.
A group of biologists, engineers, physicists, medical oncologists, pathologists and surgeons from Albert Einstein College of Medicine and Montefiore Health